NUCLEAR
South African nuclear company NTP Radioisotopes (NTP), a subsidiary of the State-owned South African Nuclear Energy Corporation (better known as Necsa), has increased its production of, and its share in the global market for, the Molybdenum-99 (Mo-99) radioisotope, the company announced on Thursday. This followed the withdrawal from the market by Canada’s NRU reactor last year.
“We have managed to grow our market share for Mo-99 through continued investment in our production, and by working with our partners to cover the supply gap,” reported NTP Group Executive Finance: Precious Hawadi. NTP’s revenues for the 2015/2016 financial year came to more than R1.2-billion, of which almost R1-billion came from radioisotopes and radiopharmaceuticals. The global market for nuclear medicine was estimated at more than $11-billion last year and is expected to reach almost $20-billion in 2021.
NTP has also highlighted that its MD, Tina Eboka, was last month re-elected as Vice-Chairperson of the Organisation for Economic Cooperation and Development Nuclear Energy Agency’s (NEA’s) High-Level Group on the Security of Supply of Medical Radioisotopes (HLG-MR). The re-election occurred during the bi-annual meeting of the group in Paris.
Please enter the email address that you used to subscribe to Research Channel. Your password will be sent to this address.
Don't have any login details?
Free Trial Access